FOR ANIMAL TREATMENT ONLY
RESTRICTED VETERINARY MEDICINE

Loxicom Injection

READ THE ENTIRE LEAFLET BEFORE USING THIS PRODUCT

PRESENTATION:
Loxicom Injection is a clear yellow solution for injection containing 5 mg **MELOXICAM** per mL (and 150 mg of ethanol as preservative) available in 10 mL or 20 mL or 100 mL multidose vials.

ACTION:
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects.
Also it reduces leukocyte infiltration into inflamed tissue.

INDICATIONS:
Dogs – For the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. And also the reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.
Cats – For the reduction of pain after surgery and management of febrile conditions when used in combination with appropriate antibiotics.

CONTRAINDICATIONS:
DO NOT USE in pregnant or lactating animals as no data has been established.
DO NOT USE in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhaging disorders or where there is evidence of individual hypersensitivity to the product.

CONSTRAINTS:
As for all NSAIDs, use in any animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided, careful clinical management may be required.
Cats: Loxicom Injection should be used as a single dose of 0.3 mg meloxicam/kg. Safety trials have demonstrated that when meloxicam is administered subcutaneously to cats (at 0.3 mg/kg) for 24 hour intervals during 3 consecutive days, there were no resulting side effects observed in trial animals.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances that are highly protein bound may compete for binding and thus lead to toxic effects. Concurrent administration of potential nephrotoxic drugs should be avoided.
Meloxicam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Pre-treatment with other anti-inflammatory drugs prior to the use of meloxicam may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Loxicom Injection. However the treatment-free period should take into account the pharmacokinetic properties of the drugs previously used.
Parenteral administration of Loxicom Injection is well tolerated without adverse reactions. Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases, elevated liver enzymes have been reported.
In very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported. These side effects generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment; but in rare cases may be serious or fatal.
In very rare cases, anaphylactoid reactions may occur and should be treated symptomatically.
If adverse reactions occur, treatment should be discontinued, and the advice of a veterinarian should be sought.
Hypovolaemia or hypotension should be corrected prior to the use of this product.
In case of overdosing, symptomatic treatment should be initiated.

USER SAFETY:
People with known hypersensitivity to NSAIDs should avoid contact with meloxicam. Meloxicam is contraindicated in women who are pregnant. Due to the risk of accidental self-injection, women who are pregnant should not administer injectable forms of meloxicam.
Hands should be washed after use. If the medicine comes into contact with the skin, the affected area should be rinsed thoroughly.

DOSAGE & ADMINISTRATION:
Dogs:
Musculoskeletal disorders:
Give a single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg of bodyweight (which is provided by 0.4 mL/10 kg bodyweight).
Meloxicam Anti-inflammatory Oral Suspension should be used for continuation of treatment, at a dosage of 0.1 mg meloxicam/kg body weight, beginning
24 hours after administration of the injection.
Reduction of post-operative pain:
Give a single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (which is provided by 0.4 mL/10 kg bodyweight) before surgery, for example at the time of induction of anaesthesia.

Cats:
Reduction of post-operative pain:
Give a single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (which is provided by 0.06 mL/kg bodyweight) directly prior to induction of anaesthesia.
Management of febrile conditions:
Give a single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (which is provided by 0.06 mL/kg bodyweight).

STORAGE:
Store below 25°C.
Once vial is broached, use contents within 28 days or discard.

WARNING
Flammable liquid and vapour
Do not use or store near heat or open flame.
Handling Precautions:
Meloxicam may possibly affect development and/or reproduction.
May cause eye irritation.
Take care to avoid accidental injection. Avoid contact with eyes.
KEEP OUT OF REACH OF CHILDREN
Environmental protection
Harmful to aquatic organisms. Avoid contamination of any water supply with product or empty container.
Disposal:
Preferably dispose of product by use. Otherwise dispose of product, packaging and waste at an approved landfill or equivalent facility.

ACVM No. A10334
See www.foodsafety.govt.nz for registration conditions.

Registered to and distributed by:
Norbrook NZ Ltd
KPMG Centre,
18 Viaduct Harbour Avenue,
Auckland.
Ph: 0800 224 022

053460I07

Norbrook®